{"id":45277,"date":"2022-06-20T18:02:11","date_gmt":"2022-06-20T16:02:11","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/best-practices-in-preparation-for-an-fda-computer-system-audit-webinar-researchandmarkets-com\/"},"modified":"2022-06-20T18:02:11","modified_gmt":"2022-06-20T16:02:11","slug":"best-practices-in-preparation-for-an-fda-computer-system-audit-webinar-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/best-practices-in-preparation-for-an-fda-computer-system-audit-webinar-researchandmarkets-com\/","title":{"rendered":"Best Practices in Preparation for an FDA Computer System Audit Webinar – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Best Practices in Preparation for an FDA Computer System Audit”<\/a> webinar has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThis webinar will focus on the key areas that are most important, including security and data integrity. Implementing and following the System Development Life Cycle (SDLC) methodology is the best approach for computer system validation and maintaining data integrity. The life cycle approach takes all aspects of validation into account throughout the life of the system and the data that it houses. The data is a key asset for any FDA-regulated company and must be protected through its entire retention period.\n<\/p>\n

\nIn preparation for an audit, it is important to assess the documentation that was prepared when each GxP system was validated to identify and remediate any gaps or issues. The FDA contact person(s) should be able to tell the story of how each system came into Production in a validated state and how each system is maintained in that validated state with the data integrity assured.\n<\/p>\n

\nIt’s important to have the right resources and understanding of the process prior to any inspection. Having the validation information available and key resources who can speak to various components of it is critical and should be arranged in advance.\n<\/p>\n

\nYou will learn some tips based on real FDA inspections and lessons learned that will be shared with the audience.\n<\/p>\n

\nWhy Should You Attend:<\/strong>\n<\/p>\n

\nFDA requires that all computer systems that handle data regulated by the Agency to be validated in accordance with their guidance on computerized systems. This guidance was first issued in 1983, and the main points of focus remain consistent today, despite the number of years that have passed and the technology changes that have taken place.\n<\/p>\n

\nThe FDA computer system guidance was revisited for its application to the medical device industry, as the first issuance addressed pharmaceuticals. In 1997, 21 CFR Part 11 was issued to address electronic records and signatures, as many laboratories and other FDA-regulated organizations began seeking ways to move into a paperless environment. This guidance has been modified over the years to make it more palatable to industry, and this includes discretionary enforcement measures. The intent was to avoid creating a huge regulatory compliance cost to industry that was initially preventing companies from embracing the technology.\n<\/p>\n

\nAdditional guidance was provided in late 2018 on Data Integrity to address an increasing trend in industry findings. We will cover best practices in industry to address these issues and ensure inspection readiness.\n<\/p>\n

\nThis session will provide some insight into current trends in compliance and enforcement. Some are based on technology changes, and these will continue to have an impact as new innovations and technology come into use in the industry. Again, we will help you position your company in a state of inspection readiness.\n<\/p>\n

\nFDA requires that all computer systems used to produce, manage and report on “GxP” (GMP, GLC, GCP) related products be validated and maintained in accordance with specific rules. This webinar will help you understand the FDA’s current thinking on computer systems that are validated and subject to inspection and audit. It will also take into account areas where FDA will likely focus their effort, including on the higher-risk systems.\n<\/p>\n

\nAs a “GxP” system, following Good Manufacturing, Laboratory and Clinical Practices, the computer system must be validated in accordance with FDA requirements. If electronic records and\/or electronic signatures (ER\/ES) are incorporated into the system, FDA’s CFR Part 11 guidance on ER\/ES must be followed.\n<\/p>\n

\nWho Should Attend:<\/strong>\n<\/p>\n

\nThis webinar is intended for those involved in planning, execution and support of computer system validation activities, working in the FDA-regulated industries, including pharmaceutical, medical device, biologics, tobacco and tobacco-related products (e-liquids, e-cigarettes, pouch tobacco, cigars, etc.).\n<\/p>\n

\nFunctions that are applicable include research and development, manufacturing, Quality Control, distribution, clinical testing and management, sample labeling, adverse events management and post-marketing surveillance.\n<\/p>\n

\nExamples of who will benefit from this webinar include:<\/strong>\n<\/p>\n